# Project 1: Fibrolamellar HCC

> **NIH NIH P50** · MAYO CLINIC ROCHESTER · 2022 · $425,451

## Abstract

PROJECT 1 – PROJECT SUMMARY
Fibrolamellar hepatocellular carcinoma (FLHCC) is an often-lethal disease affecting primarily children and
young adults. The poor prognosis is exacerbated by the lack of both existing diagnostic tests and systemic
therapy. We have recently demonstrated that there is a single, consistent deletion in one copy of chromosome
19 in FLHCC patients that results in a chimeric gene. This chimera encodes a fusion protein, a constitutively
active catalytic subunit of protein kinase A. This project has two aims: (1) develop the first diagnostic tests for
this cancer and (2) develop the first blockers for the driver for this cancer.

## Key facts

- **NIH application ID:** 10468829
- **Project number:** 5P50CA210964-05
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** MICHAEL S TORBENSON
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $425,451
- **Award type:** 5
- **Project period:** 2018-09-10 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10468829

## Citation

> US National Institutes of Health, RePORTER application 10468829, Project 1: Fibrolamellar HCC (5P50CA210964-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10468829. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*